Our results demonstrated that targeting the HPV-16 E7 oncoprotein to DCs with the αDEC205 mAb generated efficient activation of an E7-specific CD8+ T cell response and promoted enhanced therapeutic antitumor effects on TC cells in all three tumor models. The gene discussed is CD8A; the disease is neoplasm.